Exact Mass: 359.22809140000004

Exact Mass Matches: 359.22809140000004

Found 500 metabolites which its exact mass value is equals to given mass value 359.22809140000004, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

napelline

(1R,2R,4S,5S,7R,8R,9R,13R,16S,17R)-11-ethyl-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.15,8.01,10.02,8.013,17]nonadecane-4,7,16-triol

C22H33NO3 (359.2460308000001)


LSM-1634 is a kaurane diterpenoid. Napelline is a natural product found in Aconitum karakolicum, Aconitum baicalense, and other organisms with data available. 12-Epinapelline is a kaurane diterpenoid. 12-Epinapelline is a natural product found in Aconitum napellus, Delphinium leroyi, and other organisms with data available. Annotation level-1 12-Epinapelline is a diterpene alkaloid isolated from Aconitum baikalense. 12-Epinapelline exhibits Anti-inflammatory activity and stimulates the growth of colonies from fibroblast precursors[1][2]. 12-Epinapelline is a diterpene alkaloid isolated from Aconitum baikalense. 12-Epinapelline exhibits Anti-inflammatory activity and stimulates the growth of colonies from fibroblast precursors[1][2].

   

AJACONINE

7alpha,20-epoxy-21-(2-hydroxyethyl)-4-methylatid-16-en-15beta-ol

C22H33NO3 (359.2460308000001)


   

Lavoltidine

{1-methyl-5-[(3-{3-[(piperidin-1-yl)methyl]phenoxy}propyl)amino]-1H-1,2,4-triazol-3-yl}methanol

C19H29N5O2 (359.2321134)


C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent > C29702 - Histamine-2 Receptor Antagonist D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists

   

2-Hydroxylauroylcarnitine

3-[(2-hydroxydodecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H37NO5 (359.26715920000004)


2-Hydroxylauroylcarnitine is an acylcarnitine. More specifically, it is an 2-hydroxydodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy.  This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 2-Hydroxylauroylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 2-hydroxylauroylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews]. A human metabolite taken as a putative food compound of mammalian origin [HMDB]

   

Norendoxifen

4-[(1Z)-1-[4-(2-aminoethoxy)phenyl]-2-phenylbut-1-en-1-yl]phenol

C24H25NO2 (359.188519)


Norendoxifen is a metabolite of tamoxifen. Tamoxifen is an antagonist of the estrogen receptor in breast tissue via its active metabolite, hydroxytamoxifen. In other tissues such as the endometrium, it behaves as an agonist, and thus may be characterized as a mixed agonist/antagonist. Tamoxifen is the usual endocrine therapy for hormone receptor-positive breast cancer in pre-menopausal women, and is also a standard in post-menopausal women although aromatase inhibitors are also frequently used in that setting. (Wikipedia)

   

3-hydroxydodecanoyl carnitine

3-[(3-Hydroxydodecanoyl)oxy]-4-(trimethylammonio)butanoic acid

C19H37NO5 (359.26715920000004)


3-Hydroxydodecanoyl carnitine is an acylcarnitine. More specifically, it is an 3-hydroxydodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy.  This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxydodecanoyl carnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-hydroxydodecanoyl carnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

5-Hydroxydec-6-enedioylcarnitine

3-[(9-carboxy-5-hydroxynon-6-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H29NO7 (359.19439239999997)


5-Hydroxydec-6-enedioylcarnitine is an acylcarnitine. More specifically, it is an 5-hydroxydec-6-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-Hydroxydec-6-enedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 5-Hydroxydec-6-enedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

5-Hydroxydec-7-enedioylcarnitine

3-[(9-carboxy-5-hydroxynon-7-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H29NO7 (359.19439239999997)


5-Hydroxydec-7-enedioylcarnitine is an acylcarnitine. More specifically, it is an 5-hydroxydec-7-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-Hydroxydec-7-enedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 5-Hydroxydec-7-enedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

5-Hydroxydec-8-enedioylcarnitine

3-[(9-carboxy-5-hydroxynon-8-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H29NO7 (359.19439239999997)


5-Hydroxydec-8-enedioylcarnitine is an acylcarnitine. More specifically, it is an 5-hydroxydec-8-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-Hydroxydec-8-enedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 5-Hydroxydec-8-enedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

6-Hydroxydec-6-enedioylcarnitine

3-[(9-carboxy-6-hydroxynon-6-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H29NO7 (359.19439239999997)


6-Hydroxydec-6-enedioylcarnitine is an acylcarnitine. More specifically, it is an 6-hydroxydec-6-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-Hydroxydec-6-enedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 6-Hydroxydec-6-enedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

5-Hydroxydec-5-enedioylcarnitine

3-[(9-carboxy-5-hydroxynon-5-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H29NO7 (359.19439239999997)


5-Hydroxydec-5-enedioylcarnitine is an acylcarnitine. More specifically, it is an 5-hydroxydec-5-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-Hydroxydec-5-enedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 5-Hydroxydec-5-enedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(2Z)-5-Hydroxydec-2-enedioylcarnitine

3-[(9-carboxy-5-hydroxynon-2-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H29NO7 (359.19439239999997)


(2Z)-5-Hydroxydec-2-enedioylcarnitine is an acylcarnitine. More specifically, it is an (2Z)-5-hydroxydec-2-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2Z)-5-Hydroxydec-2-enedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2Z)-5-Hydroxydec-2-enedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

6-Hydroxydec-7-enedioylcarnitine

3-[(9-carboxy-6-hydroxynon-7-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H29NO7 (359.19439239999997)


6-Hydroxydec-7-enedioylcarnitine is an acylcarnitine. More specifically, it is an 6-hydroxydec-7-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-Hydroxydec-7-enedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 6-Hydroxydec-7-enedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Undecanedioylcarnitine

3-[(10-carboxydecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C18H33NO6 (359.2307758)


Undecanedioylcarnitine is an acylcarnitine. More specifically, it is an undecanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Undecanedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Undecanedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

12-Hydroxydodecanoylcarnitine

3-[(12-hydroxydodecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H37NO5 (359.26715920000004)


12-hydroxydodecanoylcarnitine is an acylcarnitine. More specifically, it is an 12-hydroxydodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 12-hydroxydodecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 12-hydroxydodecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

7-Hydroxydodecanoylcarnitine

3-[(7-hydroxydodecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H37NO5 (359.26715920000004)


7-Hydroxydodecanoylcarnitine is an acylcarnitine. More specifically, it is an 7-Hydroxydodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-Hydroxydodecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 7-Hydroxydodecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

10-Hydroxydodecanoylcarnitine

3-[(10-hydroxydodecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H37NO5 (359.26715920000004)


10-Hydroxydodecanoylcarnitine is an acylcarnitine. More specifically, it is an 10-Hydroxydodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 10-Hydroxydodecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 10-Hydroxydodecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

6-Hydroxydodecanoylcarnitine

3-[(6-Hydroxydodecanoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C19H37NO5 (359.26715920000004)


6-Hydroxydodecanoylcarnitine is an acylcarnitine. More specifically, it is an 6-Hydroxydodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-Hydroxydodecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 6-Hydroxydodecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

11-Hydroxydodecanoylcarnitine

3-[(11-hydroxydodecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H37NO5 (359.26715920000004)


11-Hydroxydodecanoylcarnitine is an acylcarnitine. More specifically, it is an 11-Hydroxydodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 11-Hydroxydodecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 11-Hydroxydodecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

5-Hydroxydodecanoylcarnitine

3-[(5-hydroxydodecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H37NO5 (359.26715920000004)


5-Hydroxydodecanoylcarnitine is an acylcarnitine. More specifically, it is an 5-Hydroxydodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-Hydroxydodecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 5-Hydroxydodecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

8-Hydroxydodecanoylcarnitine

3-[(8-Hydroxydodecanoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C19H37NO5 (359.26715920000004)


8-Hydroxydodecanoylcarnitine is an acylcarnitine. More specifically, it is an 8-Hydroxydodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 8-Hydroxydodecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 8-Hydroxydodecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

4-Hydroxydodecanoylcarnitine

3-[(4-hydroxydodecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H37NO5 (359.26715920000004)


4-Hydroxydodecanoylcarnitine is an acylcarnitine. More specifically, it is an 4-Hydroxydodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-Hydroxydodecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 4-Hydroxydodecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

9-Hydroxydodecanoylcarnitine

3-[(9-hydroxydodecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H37NO5 (359.26715920000004)


9-Hydroxydodecanoylcarnitine is an acylcarnitine. More specifically, it is an 9-Hydroxydodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 9-Hydroxydodecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 9-Hydroxydodecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

N-Palmitoyl Cysteine

tetradeca-2,4-dienedioic acid

C19H37NO3S (359.2494012000001)


N-palmitoyl cysteine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Palmitic acid amide of Cysteine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Palmitoyl Cysteine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Palmitoyl Cysteine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

N-Myristoyl Methionine

2-[(1-Hydroxytetradecylidene)amino]-4-(methylsulphanyl)butanoic acid

C19H37NO3S (359.2494012000001)


N-myristoyl methionine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Myristic acid amide of Methionine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Myristoyl Methionine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Myristoyl Methionine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

N-Eicosapentaenoyl Glycine

2-(icosa-5,8,11,14,17-pentaenamido)acetic acid

C22H33NO3 (359.2460308000001)


N-eicosapentaenoyl glycine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Eicosapentaenoic acid amide of Glycine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Eicosapentaenoyl Glycine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Eicosapentaenoyl Glycine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

Eptastigmine

1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl heptylcarbamate

C21H33N3O2 (359.25726380000003)


   

Gepirone

4,4-dimethyl-1-{4-[4-(pyrimidin-2-yl)piperazin-1-yl]butyl}piperidine-2,6-dione

C19H29N5O2 (359.2321134)


D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist N - Nervous system > N06 - Psychoanaleptics > N06A - Antidepressants Gepirone is a selective and affinitive 5-HT1A agonist. Gepirone binds selectively to 5-HT1A receptor binding site. Gepirone acts as an antidepressant agent can be used for anxiety and major depressive disorder research[1].

   

Glycyllysylarginine

2-({6-amino-2-[(2-amino-1-hydroxyethylidene)amino]-1-hydroxyhexylidene}amino)-5-carbamimidamidopentanoate

C14H29N7O4 (359.22809140000004)


   

(S)-N-Benzyl-2-((S)-2-(2-hydroxyacetyl)pyrrolidine-1-carbonyl)pyrrolidine-1-carboxamide

(S)-N-Benzyl-2-((S)-2-(2-hydroxyacetyl)pyrrolidine-1-carbonyl)pyrrolidine-1-carboxamide

C19H25N3O4 (359.184497)


   

N-Methylrosmaricine

3,4-dihydroxy-11,11-dimethyl-8-(methylamino)-5-(propan-2-yl)-16-oxatetracyclo[7.5.2.0¹,¹⁰.0²,⁷]hexadeca-2,4,6-trien-15-one

C21H29NO4 (359.20964740000005)


N-methylrosmaricine is practically insoluble (in water) and a very weakly acidic compound (based on its pKa). N-methylrosmaricine can be found in rosemary, which makes N-methylrosmaricine a potential biomarker for the consumption of this food product.

   

Pro-Pro-Phe

2-({hydroxy[1-(pyrrolidine-2-carbonyl)pyrrolidin-2-yl]methylidene}amino)-3-phenylpropanoic acid

C19H25N3O4 (359.184497)


   
   
   
   

Comosivine

O-Methylathrocupressine

C21H29NO4 (359.20964740000005)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

7alpha-Hydroxyparavallarine

7alpha-Hydroxyparavallarine

C22H33NO3 (359.2460308000001)


A natural product found in Kibatalia laurifolia.

   
   
   
   
   

(E)-methyl 4-(2-acetyl-4-oxonon-1-enyl)-6-propylnicotinate|Monasnicotinate D

(E)-methyl 4-(2-acetyl-4-oxonon-1-enyl)-6-propylnicotinate|Monasnicotinate D

C21H29NO4 (359.20964740000005)


   
   
   
   

16alpha-Hydroxy;B,HCl-Paravallarine

16alpha-Hydroxy;B,HCl-Paravallarine

C22H33NO3 (359.2460308000001)


   

1-dehydroxy-1,2-dehydrokaracoline|delpoline

1-dehydroxy-1,2-dehydrokaracoline|delpoline

C22H33NO3 (359.2460308000001)


   

trichosetin

trichosetin

C21H29NO4 (359.20964740000005)


A member of the class of octahydronaphthalenes that is (2R,4aS,5R,6R,8aS)-2,5-dimethyl-6-[(1E)-prop-1-en-1-yl]-1,2,3,4,4a,5,6,8a-octahydronaphthalene in which the hydrogen at position 5 has been replaced by a (Z)-hydroxy[(5S)-5-(hydroxymethyl)-2,4-dioxopyrrolidin-3-ylidene]methyl group. Produced by the dual culture of Trichoderma harzianum and Catharanthus roseus callus, it exhibits significant antimicrobial activity against Gram-positive bacteria such as Staphylococcus aureus and Bacillus subtilis.

   
   
   
   
   
   
   
   
   
   
   
   
   
   

glycylglutaminylarginine

glycylglutaminylarginine

C13H25N7O5 (359.191708)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

MLS002153959-01!Napelline5008-52-6

MLS002153959-01!Napelline5008-52-6

C22H33NO3 (359.2460308000001)


   
   

Luciculine

Luciculine

C22H33NO3 (359.2460308000001)


Origin: Plant; Formula(Parent): C22H33NO3; Bottle Name:Napelline; PRIME Parent Name:Napelline; PRIME in-house No.:V0349; SubCategory_DNP: Terpenoid alkaloids, Diterpene alkaloid, Aconitum alkaloid

   

Ala Ala Ala Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]propanamido]propanamido]hexanoic acid

C15H29N5O5 (359.21685840000004)


   

Ala Ala Ala Gln

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]propanamido]propanamido]-4-carbamoylbutanoic acid

C14H25N5O6 (359.180475)


   

Ala Ala Lys Ala

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-aminopropanamido]propanamido]hexanamido]propanoic acid

C15H29N5O5 (359.21685840000004)


   

Ala Ala Gln Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]propanamido]-4-carbamoylbutanamido]propanoic acid

C14H25N5O6 (359.180475)


   

Ala Gly Gly Arg

(2S)-2-(2-{2-[(2S)-2-aminopropanamido]acetamido}acetamido)-5-carbamimidamidopentanoic acid

C13H25N7O5 (359.191708)


   

Ala Gly Asn Val

(2S)-2-[(2S)-2-{2-[(2S)-2-aminopropanamido]acetamido}-3-carbamoylpropanamido]-3-methylbutanoic acid

C14H25N5O6 (359.180475)


   

Ala Gly Arg Gly

2-[(2S)-2-{2-[(2S)-2-aminopropanamido]acetamido}-5-carbamimidamidopentanamido]acetic acid

C13H25N7O5 (359.191708)


   

Ala Gly Val Asn

(2S)-2-[(2S)-2-{2-[(2S)-2-aminopropanamido]acetamido}-3-methylbutanamido]-3-carbamoylpropanoic acid

C14H25N5O6 (359.180475)


   

Ala Lys Ala Ala

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-aminopropanamido]hexanamido]propanamido]propanoic acid

C15H29N5O5 (359.21685840000004)


   

Ala Asn Gly Val

(2S)-2-{2-[(2S)-2-[(2S)-2-aminopropanamido]-3-carbamoylpropanamido]acetamido}-3-methylbutanoic acid

C14H25N5O6 (359.180475)


   

Ala Asn Val Gly

2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-carbamoylpropanamido]-3-methylbutanamido]acetic acid

C14H25N5O6 (359.180475)


   

Ala Gln Ala Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-4-carbamoylbutanamido]propanamido]propanoic acid

C14H25N5O6 (359.180475)


   

Ala Arg Gly Gly

2-{2-[(2S)-2-[(2S)-2-aminopropanamido]-5-carbamimidamidopentanamido]acetamido}acetic acid

C13H25N7O5 (359.191708)


   

Ala Val Gly Asn

(2S)-2-{2-[(2S)-2-[(2S)-2-aminopropanamido]-3-methylbutanamido]acetamido}-3-carbamoylpropanoic acid

C14H25N5O6 (359.180475)


   

Ala Val Asn Gly

2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-methylbutanamido]-3-carbamoylpropanamido]acetic acid

C14H25N5O6 (359.180475)


   

Gly Ala Gly Arg

(2S)-2-{2-[(2S)-2-(2-aminoacetamido)propanamido]acetamido}-5-carbamimidamidopentanoic acid

C13H25N7O5 (359.191708)


   

Gly Ala Asn Val

(2S)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)propanamido]-3-carbamoylpropanamido]-3-methylbutanoic acid

C14H25N5O6 (359.180475)


   

Gly Ala Arg Gly

2-[(2S)-2-[(2S)-2-(2-aminoacetamido)propanamido]-5-carbamimidamidopentanamido]acetic acid

C13H25N7O5 (359.191708)


   

Gly Ala Val Asn

(2S)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)propanamido]-3-methylbutanamido]-3-carbamoylpropanoic acid

C14H25N5O6 (359.180475)


   

Gly Gly Ala Arg

(2S)-2-[(2S)-2-[2-(2-aminoacetamido)acetamido]propanamido]-5-carbamimidamidopentanoic acid

C13H25N7O5 (359.191708)


   

Gly Gly Ile Asn

(2S)-2-[(2S,3S)-2-[2-(2-aminoacetamido)acetamido]-3-methylpentanamido]-3-carbamoylpropanoic acid

C14H25N5O6 (359.180475)


   

Gly Gly Lys Val

(2S)-2-[(2S)-6-amino-2-[2-(2-aminoacetamido)acetamido]hexanamido]-3-methylbutanoic acid

C15H29N5O5 (359.21685840000004)


   

Gly Gly Leu Asn

(2S)-2-[(2S)-2-[2-(2-aminoacetamido)acetamido]-4-methylpentanamido]-3-carbamoylpropanoic acid

C14H25N5O6 (359.180475)


   

Gly Gly Asn Ile

(2S,3S)-2-[(2S)-2-[2-(2-aminoacetamido)acetamido]-3-carbamoylpropanamido]-3-methylpentanoic acid

C14H25N5O6 (359.180475)


   

Gly Gly Asn Leu

(2S)-2-[(2S)-2-[2-(2-aminoacetamido)acetamido]-3-carbamoylpropanamido]-4-methylpentanoic acid

C14H25N5O6 (359.180475)


   

Gly Gly Gln Val

(2S)-2-[(2S)-2-[2-(2-aminoacetamido)acetamido]-4-carbamoylbutanamido]-3-methylbutanoic acid

C14H25N5O6 (359.180475)


   

Gly Gly Arg Ala

(2S)-2-[(2S)-2-[2-(2-aminoacetamido)acetamido]-5-carbamimidamidopentanamido]propanoic acid

C13H25N7O5 (359.191708)


   

Gly Gly Val Lys

(2S)-6-amino-2-[(2S)-2-[2-(2-aminoacetamido)acetamido]-3-methylbutanamido]hexanoic acid

C15H29N5O5 (359.21685840000004)


   

Gly Gly Val Gln

(2S)-2-[(2S)-2-[2-(2-aminoacetamido)acetamido]-3-methylbutanamido]-4-carbamoylbutanoic acid

C14H25N5O6 (359.180475)


   

Gly Ile Gly Asn

(2S)-2-{2-[(2S,3S)-2-(2-aminoacetamido)-3-methylpentanamido]acetamido}-3-carbamoylpropanoic acid

C14H25N5O6 (359.180475)


   

Gly Ile Asn Gly

2-[(2S)-2-[(2S,3S)-2-(2-aminoacetamido)-3-methylpentanamido]-3-carbamoylpropanamido]acetic acid

C14H25N5O6 (359.180475)


   

Gly Lys Gly Val

(2S)-2-{2-[(2S)-6-amino-2-(2-aminoacetamido)hexanamido]acetamido}-3-methylbutanoic acid

C15H29N5O5 (359.21685840000004)


   

Gly Lys Val Gly

2-[(2S)-2-[(2S)-6-amino-2-(2-aminoacetamido)hexanamido]-3-methylbutanamido]acetic acid

C15H29N5O5 (359.21685840000004)


   

Gly Leu Gly Asn

(2S)-2-{2-[(2S)-2-(2-aminoacetamido)-4-methylpentanamido]acetamido}-3-carbamoylpropanoic acid

C14H25N5O6 (359.180475)


   

Gly Leu Asn Gly

2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-4-methylpentanamido]-3-carbamoylpropanamido]acetic acid

C14H25N5O6 (359.180475)


   

Gly Asn Ala Val

(2S)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-carbamoylpropanamido]propanamido]-3-methylbutanoic acid

C14H25N5O6 (359.180475)


   

Gly Asn Gly Ile

(2S,3S)-2-{2-[(2S)-2-(2-aminoacetamido)-3-carbamoylpropanamido]acetamido}-3-methylpentanoic acid

C14H25N5O6 (359.180475)


   

Gly Asn Gly Leu

(2S)-2-{2-[(2S)-2-(2-aminoacetamido)-3-carbamoylpropanamido]acetamido}-4-methylpentanoic acid

C14H25N5O6 (359.180475)


   

Gly Asn Ile Gly

2-[(2S,3S)-2-[(2S)-2-(2-aminoacetamido)-3-carbamoylpropanamido]-3-methylpentanamido]acetic acid

C14H25N5O6 (359.180475)


   

Gly Asn Leu Gly

2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-carbamoylpropanamido]-4-methylpentanamido]acetic acid

C14H25N5O6 (359.180475)


   

Gly Asn Val Ala

(2S)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-carbamoylpropanamido]-3-methylbutanamido]propanoic acid

C14H25N5O6 (359.180475)


   

Gly Gln Gly Val

(2S)-2-{2-[(2S)-2-(2-aminoacetamido)-4-carbamoylbutanamido]acetamido}-3-methylbutanoic acid

C14H25N5O6 (359.180475)


   

Gly Gln Val Gly

2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-4-carbamoylbutanamido]-3-methylbutanamido]acetic acid

C14H25N5O6 (359.180475)


   

Gly Arg Ala Gly

2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-5-carbamimidamidopentanamido]propanamido]acetic acid

C13H25N7O5 (359.191708)


   

Gly Arg Gly Ala

(2S)-2-{2-[(2S)-2-(2-aminoacetamido)-5-carbamimidamidopentanamido]acetamido}propanoic acid

C13H25N7O5 (359.191708)


   

Gly Val Ala Asn

(2S)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-methylbutanamido]propanamido]-3-carbamoylpropanoic acid

C14H25N5O6 (359.180475)


   

Gly Val Gly Lys

(2S)-6-amino-2-{2-[(2S)-2-(2-aminoacetamido)-3-methylbutanamido]acetamido}hexanoic acid

C15H29N5O5 (359.21685840000004)


   

Gly Val Gly Gln

(2S)-2-{2-[(2S)-2-(2-aminoacetamido)-3-methylbutanamido]acetamido}-4-carbamoylbutanoic acid

C14H25N5O6 (359.180475)


   

Gly Val Lys Gly

2-[(2S)-6-amino-2-[(2S)-2-(2-aminoacetamido)-3-methylbutanamido]hexanamido]acetic acid

C15H29N5O5 (359.21685840000004)


   

Gly Val Asn Ala

(2S)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-methylbutanamido]-3-carbamoylpropanamido]propanoic acid

C14H25N5O6 (359.180475)


   

Gly Val Gln Gly

2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-methylbutanamido]-4-carbamoylbutanamido]acetic acid

C14H25N5O6 (359.180475)


   
   

Ile Gly Gly Asn

(2S)-2-(2-{2-[(2S,3S)-2-amino-3-methylpentanamido]acetamido}acetamido)-3-carbamoylpropanoic acid

C14H25N5O6 (359.180475)


   

Ile Gly Asn Gly

2-[(2S)-2-{2-[(2S,3S)-2-amino-3-methylpentanamido]acetamido}-3-carbamoylpropanamido]acetic acid

C14H25N5O6 (359.180475)


   

Ile Asn Gly Gly

2-{2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-carbamoylpropanamido]acetamido}acetic acid

C14H25N5O6 (359.180475)


   

Lys Ala Ala Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]propanamido]propanamido]propanoic acid

C15H29N5O5 (359.21685840000004)


   

Lys Gly Gly Val

(2S)-2-(2-{2-[(2S)-2,6-diaminohexanamido]acetamido}acetamido)-3-methylbutanoic acid

C15H29N5O5 (359.21685840000004)


   

Lys Gly Val Gly

2-[(2S)-2-{2-[(2S)-2,6-diaminohexanamido]acetamido}-3-methylbutanamido]acetic acid

C15H29N5O5 (359.21685840000004)


   
   
   
   
   

Lys Val Gly Gly

2-{2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-methylbutanamido]acetamido}acetic acid

C15H29N5O5 (359.21685840000004)


   
   

Leu Gly Gly Asn

(2S)-2-(2-{2-[(2S)-2-amino-4-methylpentanamido]acetamido}acetamido)-3-carbamoylpropanoic acid

C14H25N5O6 (359.180475)


   

Leu Gly Asn Gly

2-[(2S)-2-{2-[(2S)-2-amino-4-methylpentanamido]acetamido}-3-carbamoylpropanamido]acetic acid

C14H25N5O6 (359.180475)


   

Leu Asn Gly Gly

2-{2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-3-carbamoylpropanamido]acetamido}acetic acid

C14H25N5O6 (359.180475)


   
   
   

Asn Ala Gly Val

(2S)-2-{2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]propanamido]acetamido}-3-methylbutanoic acid

C14H25N5O6 (359.180475)


   

Asn Ala Val Gly

2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]propanamido]-3-methylbutanamido]acetic acid

C14H25N5O6 (359.180475)


   

Asn Gly Ala Val

(2S)-2-[(2S)-2-{2-[(2S)-2-amino-3-carbamoylpropanamido]acetamido}propanamido]-3-methylbutanoic acid

C14H25N5O6 (359.180475)


   

Asn Gly Gly Ile

(2S,3S)-2-(2-{2-[(2S)-2-amino-3-carbamoylpropanamido]acetamido}acetamido)-3-methylpentanoic acid

C14H25N5O6 (359.180475)


   

Asn Gly Gly Leu

(2S)-2-(2-{2-[(2S)-2-amino-3-carbamoylpropanamido]acetamido}acetamido)-4-methylpentanoic acid

C14H25N5O6 (359.180475)


   

Asn Gly Ile Gly

2-[(2S,3S)-2-{2-[(2S)-2-amino-3-carbamoylpropanamido]acetamido}-3-methylpentanamido]acetic acid

C14H25N5O6 (359.180475)


   

Asn Gly Leu Gly

2-[(2S)-2-{2-[(2S)-2-amino-3-carbamoylpropanamido]acetamido}-4-methylpentanamido]acetic acid

C14H25N5O6 (359.180475)


   

Asn Gly Val Ala

(2S)-2-[(2S)-2-{2-[(2S)-2-amino-3-carbamoylpropanamido]acetamido}-3-methylbutanamido]propanoic acid

C14H25N5O6 (359.180475)


   

Asn Ile Gly Gly

2-{2-[(2S,3S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-methylpentanamido]acetamido}acetic acid

C14H25N5O6 (359.180475)


   

Asn Leu Gly Gly

2-{2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-4-methylpentanamido]acetamido}acetic acid

C14H25N5O6 (359.180475)


   
   

Asn Val Ala Gly

2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-methylbutanamido]propanamido]acetic acid

C14H25N5O6 (359.180475)


   

Asn Val Gly Ala

(2S)-2-{2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-methylbutanamido]acetamido}propanoic acid

C14H25N5O6 (359.180475)


   
   

Gln Ala Ala Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]propanamido]propanamido]propanoic acid

C14H25N5O6 (359.180475)


   

Gln Gly Gly Val

(2S)-2-(2-{2-[(2S)-2-amino-4-carbamoylbutanamido]acetamido}acetamido)-3-methylbutanoic acid

C14H25N5O6 (359.180475)


   

Gln Gly Val Gly

2-[(2S)-2-{2-[(2S)-2-amino-4-carbamoylbutanamido]acetamido}-3-methylbutanamido]acetic acid

C14H25N5O6 (359.180475)


   

Gln Val Gly Gly

2-{2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-3-methylbutanamido]acetamido}acetic acid

C14H25N5O6 (359.180475)


   

Arg Ala Gly Gly

2-{2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]propanamido]acetamido}acetic acid

C13H25N7O5 (359.191708)


   

Arg Gly Ala Gly

2-[(2S)-2-{2-[(2S)-2-amino-5-carbamimidamidopentanamido]acetamido}propanamido]acetic acid

C13H25N7O5 (359.191708)


   

Arg Gly Gly Ala

(2S)-2-(2-{2-[(2S)-2-amino-5-carbamimidamidopentanamido]acetamido}acetamido)propanoic acid

C13H25N7O5 (359.191708)


   
   
   
   
   

Val Ala Gly Asn

(2S)-2-{2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]propanamido]acetamido}-3-carbamoylpropanoic acid

C14H25N5O6 (359.180475)


   
   

Val Gly Gly Lys

(2S)-6-amino-2-(2-{2-[(2S)-2-amino-3-methylbutanamido]acetamido}acetamido)hexanoic acid

C15H29N5O5 (359.21685840000004)


   

Val Gly Lys Gly

2-[(2S)-6-amino-2-{2-[(2S)-2-amino-3-methylbutanamido]acetamido}hexanamido]acetic acid

C15H29N5O5 (359.21685840000004)


   

Val Lys Gly Gly

2-{2-[(2S)-6-amino-2-[(2S)-2-amino-3-methylbutanamido]hexanamido]acetamido}acetic acid

C15H29N5O5 (359.21685840000004)


   

CAR 12:0;O

3-[(3-hydroxydodecanoyl)oxy]-4-(trimethylammonio)butanoate;3-hydroxylauroylcarnitine

C19H37NO5 (359.26715920000004)


   
   

(2S)-2-[bis(3,5-dimethylphenyl)-methoxymethyl]pyrrolidine,hydrochloride

(2S)-2-[bis(3,5-dimethylphenyl)-methoxymethyl]pyrrolidine,hydrochloride

C22H30ClNO (359.20158000000004)


   
   

(S,S)-3-CBZ-3,6-DIAZABICYCLO[3.2.0]HEPTANE

(S,S)-3-CBZ-3,6-DIAZABICYCLO[3.2.0]HEPTANE

C21H33N3O2 (359.25726380000003)


   

Cyclomethycaine

3-(2-methylpiperidin-1-yl)propyl 4-cyclohexyloxybenzoate

C22H33NO3 (359.2460308000001)


C78272 - Agent Affecting Nervous System > C245 - Anesthetic Agent

   
   

tert-Butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate

tert-Butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate

C20H30BNO4 (359.226777)


   

1-BOC-4-[CARBOXY-(1H-INDOL-2-YL)-METHYL]-PIPERAZINE

1-BOC-4-[CARBOXY-(1H-INDOL-2-YL)-METHYL]-PIPERAZINE

C19H25N3O4 (359.184497)


   

[5-(4-methylpiperazin-1-yl)-1-[(2-methylpropan-2-yl)oxycarbonyl]indol-2-yl]boronic acid

[5-(4-methylpiperazin-1-yl)-1-[(2-methylpropan-2-yl)oxycarbonyl]indol-2-yl]boronic acid

C18H26BN3O4 (359.20162660000005)


   

3-(4-BOC-PIPERAZIN-1-YL-METHYL)-5-TRIFLUOROMETHYLANILINE

3-(4-BOC-PIPERAZIN-1-YL-METHYL)-5-TRIFLUOROMETHYLANILINE

C17H24F3N3O2 (359.182052)


   

PIFZER CALCIUM-SENSING PARATHYROID HORMONE RECEPTORS ANTAGONISTS

PIFZER CALCIUM-SENSING PARATHYROID HORMONE RECEPTORS ANTAGONISTS

C23H25N3O (359.199752)


   

2-[2-(2-ethoxypyridin-3-yl)oxyethoxy]-3-(2-methylpiperazin-1-yl)pyrazine

2-[2-(2-ethoxypyridin-3-yl)oxyethoxy]-3-(2-methylpiperazin-1-yl)pyrazine

C18H25N5O3 (359.19573)


   

Tert-Butyl 6-(4,4,5,5-Tetramethyl-1,3,2-Dioxaborolan-2-Yl)-3,4-Dihydroisoquinoline-2(1H)-Carboxylate

Tert-Butyl 6-(4,4,5,5-Tetramethyl-1,3,2-Dioxaborolan-2-Yl)-3,4-Dihydroisoquinoline-2(1H)-Carboxylate

C20H30BNO4 (359.226777)


   

(3-BOC-AMINO-PIPERIDIN-1-YL)-(1H-INDOL-2-YL)-ACETICACID

(3-BOC-AMINO-PIPERIDIN-1-YL)-(1H-INDOL-2-YL)-ACETICACID

C19H25N3O4 (359.184497)


   

2-(7-Amino-1-isoquinolinyl)imidodicarbonic acid 1,3-bis(1,1-dimethylethyl) ester

2-(7-Amino-1-isoquinolinyl)imidodicarbonic acid 1,3-bis(1,1-dimethylethyl) ester

C19H25N3O4 (359.184497)


   

2,4-Diphenyl-6-(4,4,5,5-tetramethyl-[1,3,2] dioxaborolan-2-yl)-[1,3,5]triazine

2,4-Diphenyl-6-(4,4,5,5-tetramethyl-[1,3,2] dioxaborolan-2-yl)-[1,3,5]triazine

C21H22BN3O2 (359.1804982)


   

4-[2-(1,3-DIHYDRO-1,3DIOXO-2H-ISOINDOL-YL)ETHYL]-1-PIPERAZINECARBOXYLIC ACID, 1,1-DIMETHYLETHYL ESTER

4-[2-(1,3-DIHYDRO-1,3DIOXO-2H-ISOINDOL-YL)ETHYL]-1-PIPERAZINECARBOXYLIC ACID, 1,1-DIMETHYLETHYL ESTER

C19H25N3O4 (359.184497)


   

4-((2S)PYRROLIDIN-2-YL)-1,2-BIS(PHENYLMETHOXY)BENZENE

4-((2S)PYRROLIDIN-2-YL)-1,2-BIS(PHENYLMETHOXY)BENZENE

C24H25NO2 (359.188519)


   

1-Piperidinepropanoic acid, 4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-oxo-, ethyl ester, (3R,4R)-

1-Piperidinepropanoic acid, 4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-oxo-, ethyl ester, (3R,4R)-

C18H25N5O3 (359.19573)


   

Glucagon receptor antagonists-2

Glucagon receptor antagonists-2

C22H30FNO2 (359.2260452)


   

Glucagon receptor antagonists-3

Glucagon receptor antagonists-3

C22H30FNO2 (359.2260452)


   

4-(4-BOC-PIPERAZIN-1-YL-METHYL)-2-TRIFLUOROMETHYLANILINE

4-(4-BOC-PIPERAZIN-1-YL-METHYL)-2-TRIFLUOROMETHYLANILINE

C17H24F3N3O2 (359.182052)


   

Florbetaben F-18

Florbetaben F-18

C21H26FNO3 (359.18966180000007)


V - Various > V09 - Diagnostic radiopharmaceuticals > V09A - Central nervous system C1446 - Radiopharmaceutical Compound > C2124 - Radioconjugate

   
   

D-Leucyl-N-(4-Carbamimidoylbenzyl)-L-Prolinamide

D-Leucyl-N-(4-Carbamimidoylbenzyl)-L-Prolinamide

C19H29N5O2 (359.2321134)


   

Bufetolol hydrochloride

Bufetolol hydrochloride

C18H30ClNO4 (359.18632500000007)


D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists

   

2-(3,4-Dimethoxyphenyl)-n-[2-(3,4-dimethoxyphenyl)ethyl]-n-methylethanamine

2-(3,4-Dimethoxyphenyl)-n-[2-(3,4-dimethoxyphenyl)ethyl]-n-methylethanamine

C21H29NO4 (359.20964740000005)


   

3-[(R)-[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-hydroxymethyl]-2-methoxyphenol

3-[(R)-[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-hydroxymethyl]-2-methoxyphenol

C21H26FNO3 (359.18966180000007)


   

Isopyrazam, anti-(+/-)-

Isopyrazam, anti-(+/-)-

C20H23F2N3O (359.1809092)


   
   

3-[(S)-[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-hydroxymethyl]-2-methoxyphenol

3-[(S)-[1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]-hydroxymethyl]-2-methoxyphenol

C21H26FNO3 (359.18966180000007)


   
   

N-[(2R)-2-{[(2S)-2-(1,3-Benzoxazol-2-yl)pyrrolidin-1-yl]carbonyl}hexyl]-N-hydroxyformamide

N-[(2R)-2-{[(2S)-2-(1,3-Benzoxazol-2-yl)pyrrolidin-1-yl]carbonyl}hexyl]-N-hydroxyformamide

C19H25N3O4 (359.184497)


   

[(3,7,11-Trimethyl-dodeca-2,6,10-trienyloxycarbamoyl)-methyl]-phosphonic acid

[(3,7,11-Trimethyl-dodeca-2,6,10-trienyloxycarbamoyl)-methyl]-phosphonic acid

C17H30NO5P (359.18615)


   

1-(4-Piperidylmethyl)-3-(3-quinolyl)pyrazolo[3,4-d]pyrimidin-4-amine

1-(4-Piperidylmethyl)-3-(3-quinolyl)pyrazolo[3,4-d]pyrimidin-4-amine

C20H21N7 (359.1858346)


   

cannabigerolate

cannabigerolate

C22H31O4- (359.2222226)


A dihydroxybenzoate that is the conjugate base of cannabigerolic acid, obtained by deprotonation of the carboxy group.

   

Cannabinerolate

Cannabinerolate

C22H31O4- (359.2222226)


A dihydroxybenzoate that is the conjugate base of cannabinerolic acid, obtained by deprotonation of the carboxy group.

   

(4Z,7Z,10Z,13Z,15E,17S,19Z)-17-hydroperoxydocosa-4,7,10,13,15,19-hexaenoate

(4Z,7Z,10Z,13Z,15E,17S,19Z)-17-hydroperoxydocosa-4,7,10,13,15,19-hexaenoate

C22H31O4- (359.2222226)


   

9alpha-Hydroxy-3-oxo-23,24-bisnorchol-4-en-22-oate

9alpha-Hydroxy-3-oxo-23,24-bisnorchol-4-en-22-oate

C22H31O4- (359.2222226)


   

17R-hydroperoxydocosahexaenoate

17R-hydroperoxydocosahexaenoate

C22H31O4- (359.2222226)


   

Pregn-4-en-3-one-22-oate

Pregn-4-en-3-one-22-oate

C22H31O4- (359.2222226)


   

Undecanedioylcarnitine

Undecanedioylcarnitine

C18H33NO6 (359.2307758)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

(2Z)-5-Hydroxydec-2-enedioylcarnitine

(2Z)-5-Hydroxydec-2-enedioylcarnitine

C17H29NO7 (359.19439239999997)


   

Leu-Leu-Asp

Leu-Leu-Asp

C16H29N3O6 (359.20562540000003)


A tripeptide composed of two L-leucine units joined to L-aspartic acid by a peptide linkage.

   

Glu-Ile-Val

Glu-Ile-Val

C16H29N3O6 (359.20562540000003)


A tripeptide composed of L-glutamic acid, L-isoleucine and L-valine joined in sequence by peptide linkages.

   

Phe-Pro-Pro

Phe-Pro-Pro

C19H25N3O4 (359.184497)


A tripeptide composed of L-phenylalanine and two L-proline units joined by peptide linkages.

   

N-cycloheptyl-3-(2-methoxyethyl)-2,4-dioxo-1H-quinazoline-7-carboxamide

N-cycloheptyl-3-(2-methoxyethyl)-2,4-dioxo-1H-quinazoline-7-carboxamide

C19H25N3O4 (359.184497)


   

5-(diethylamino)-2-[(E)-(diphenylhydrazinylidene)methyl]phenol

5-(diethylamino)-2-[(E)-(diphenylhydrazinylidene)methyl]phenol

C23H25N3O (359.199752)


   

14-Hpdhe(1-)

14-Hpdhe(1-)

C22H31O4- (359.2222226)


A polyunsaturated fatty acid anion that is the conjugate base of 14-HPDHE, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

14(S)-Hpdhe(1-)

14(S)-Hpdhe(1-)

C22H31O4- (359.2222226)


A polyunsaturated fatty acid anion that is the conjugate base of 14(S)-HPDHE, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

N-[3-(1-azepanyl)propyl]-1-ethylsulfonyl-4-piperidinecarboxamide

N-[3-(1-azepanyl)propyl]-1-ethylsulfonyl-4-piperidinecarboxamide

C17H33N3O3S (359.22425080000005)


   

1-[6-Amino-2,4-dioxo-1-(phenylmethyl)-5-pyrimidinyl]-3-butyl-1-ethylurea

1-[6-Amino-2,4-dioxo-1-(phenylmethyl)-5-pyrimidinyl]-3-butyl-1-ethylurea

C18H25N5O3 (359.19573)


   

5-[1-[3-(4-Ethylphenoxy)propylamino]ethylidene]-1,3-dimethyl-1,3-diazinane-2,4,6-trione

5-[1-[3-(4-Ethylphenoxy)propylamino]ethylidene]-1,3-dimethyl-1,3-diazinane-2,4,6-trione

C19H25N3O4 (359.184497)


   

2,4-dioxo-3-(2-oxolanylmethyl)-N-pentyl-1H-quinazoline-7-carboxamide

2,4-dioxo-3-(2-oxolanylmethyl)-N-pentyl-1H-quinazoline-7-carboxamide

C19H25N3O4 (359.184497)


   

(13R,14S)-dihydroxy-(4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoate

(13R,14S)-dihydroxy-(4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoate

C22H31O4- (359.2222226)


A docosanoid anion that is the conjugate base of (13R,14S)-dihydroxy-(4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

1-ethyl-N-heptanoyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbohydrazide

1-ethyl-N-heptanoyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbohydrazide

C19H25N3O4 (359.184497)


   
   
   

(4Z,7Z,11E,13Z,16Z,19Z)-10-hydroperoxydocosa-4,7,11,13,16,19-hexaenoate

(4Z,7Z,11E,13Z,16Z,19Z)-10-hydroperoxydocosa-4,7,11,13,16,19-hexaenoate

C22H31O4- (359.2222226)


   
   
   
   
   
   
   
   

syn-(1S,4R,9S)-isopyrazam

syn-(1S,4R,9S)-isopyrazam

C20H23F2N3O (359.1809092)


   

anti-(1S,4R,9R)-isopyrazam

anti-(1S,4R,9R)-isopyrazam

C20H23F2N3O (359.1809092)


   

1-(4-methylphenyl)-2-[3-(4-methylphenyl)-6,7,8,9-tetrahydro-5H-imidazo[1,2-a]azepin-1-ium-1-yl]ethanone

1-(4-methylphenyl)-2-[3-(4-methylphenyl)-6,7,8,9-tetrahydro-5H-imidazo[1,2-a]azepin-1-ium-1-yl]ethanone

C24H27N2O+ (359.2123272)


   
   
   
   

(2S,3S,3aR,9bR)-1-[cyclobutyl(oxo)methyl]-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide

(2S,3S,3aR,9bR)-1-[cyclobutyl(oxo)methyl]-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide

C19H25N3O4 (359.184497)


   

(1S,9R,10R,11R)-12-acetyl-N-cyclopentyl-10-(hydroxymethyl)-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide

(1S,9R,10R,11R)-12-acetyl-N-cyclopentyl-10-(hydroxymethyl)-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide

C19H25N3O4 (359.184497)


   

(1R,9S,10S,11S)-12-acetyl-N-cyclopentyl-10-(hydroxymethyl)-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide

(1R,9S,10S,11S)-12-acetyl-N-cyclopentyl-10-(hydroxymethyl)-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide

C19H25N3O4 (359.184497)


   

N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide

N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide

C19H25N3O4 (359.184497)


   

N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide

N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide

C19H25N3O4 (359.184497)


   

N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide

N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide

C19H25N3O4 (359.184497)


   

N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide

N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide

C19H25N3O4 (359.184497)


   

N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide

N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide

C19H25N3O4 (359.184497)


   

N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide

N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide

C19H25N3O4 (359.184497)


   

N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide

N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide

C19H25N3O4 (359.184497)


   

N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide

N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide

C19H25N3O4 (359.184497)


   

(2R,3R,3aS,9bS)-1-[cyclobutyl(oxo)methyl]-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide

(2R,3R,3aS,9bS)-1-[cyclobutyl(oxo)methyl]-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide

C19H25N3O4 (359.184497)


   
   
   
   
   
   
   
   
   
   
   

neuroprotectin D1 anion

neuroprotectin D1 anion

C22H31O4- (359.2222226)


   
   

(4Z,7S,8E,10E,12Z,14S,16Z,19Z)-7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoate

(4Z,7S,8E,10E,12Z,14S,16Z,19Z)-7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoate

C22H31O4- (359.2222226)


   

13-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]tridecanoate

13-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]tridecanoate

C19H35O6- (359.243351)


   
   

(5Z,7S,8E,10Z,13Z,15Z,17S,19Z)-7,17-dihydroxydocosa-5,8,10,13,15,19-hexaenoate

(5Z,7S,8E,10Z,13Z,15Z,17S,19Z)-7,17-dihydroxydocosa-5,8,10,13,15,19-hexaenoate

C22H31O4- (359.2222226)


   

(4Z,8E,10Z,12E,14S,16Z,19Z)-14-hydroperoxydocosa-4,8,10,12,16,19-hexaenoate

(4Z,8E,10Z,12E,14S,16Z,19Z)-14-hydroperoxydocosa-4,8,10,12,16,19-hexaenoate

C22H31O4- (359.2222226)


   

10(R),17(R)-dihydroxydocosa-4Z,7Z,11E,13E,15Z,19Z-hexaenoate

10(R),17(R)-dihydroxydocosa-4Z,7Z,11E,13E,15Z,19Z-hexaenoate

C22H31O4- (359.2222226)


   

(14S,21R)-dihydroxy-(4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoate

(14S,21R)-dihydroxy-(4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoate

C22H31O4- (359.2222226)


   

(14R,21R)-dihydroxy-(4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoate

(14R,21R)-dihydroxy-(4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoate

C22H31O4- (359.2222226)


   

(14S,21S)-dihydroxy-(4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoate

(14S,21S)-dihydroxy-(4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoate

C22H31O4- (359.2222226)


   

(14R,21S)-dihydroxy-(4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoate

(14R,21S)-dihydroxy-(4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoate

C22H31O4- (359.2222226)


   

6-{3-[(1E,3E,5Z,7E,11Z)-9-hydroxytetradeca-1,3,5,7,11-pentaen-1-yl]oxiran-2-yl}hexanoate

6-{3-[(1E,3E,5Z,7E,11Z)-9-hydroxytetradeca-1,3,5,7,11-pentaen-1-yl]oxiran-2-yl}hexanoate

C22H31O4- (359.2222226)


   

(7R,14S)-dihydroxy-(4Z,8E,10E,12Z,16Z,19Z)-docosahexaenoate

(7R,14S)-dihydroxy-(4Z,8E,10E,12Z,16Z,19Z)-docosahexaenoate

C22H31O4- (359.2222226)


   

12-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-oxododecanoate

12-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-oxododecanoate

C18H31O7- (359.2069676)


   

(11R)-11-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-oxododecanoate

(11R)-11-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-oxododecanoate

C18H31O7- (359.2069676)


   

(12R)-12-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxytridecanoate

(12R)-12-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxytridecanoate

C19H35O6- (359.243351)


   
   

(3Z,5S)-3-[(2E,6R,8E,10E,12E)-1-hydroxy-2,6-dimethyltetradeca-2,8,10,12-tetraenylidene]-5-(hydroxymethyl)pyrrolidine-2,4-dione

(3Z,5S)-3-[(2E,6R,8E,10E,12E)-1-hydroxy-2,6-dimethyltetradeca-2,8,10,12-tetraenylidene]-5-(hydroxymethyl)pyrrolidine-2,4-dione

C21H29NO4 (359.20964740000005)


   

(1R,2R,4S,5S,7R,8R,9R,10S,13R,16S,17R)-11-ethyl-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.15,8.01,10.02,8.013,17]nonadecane-4,7,16-triol

(1R,2R,4S,5S,7R,8R,9R,10S,13R,16S,17R)-11-ethyl-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.15,8.01,10.02,8.013,17]nonadecane-4,7,16-triol

C22H33NO3 (359.2460308000001)


   

(1R,2R,4S,5S,7R,8R,9R,10R,13R,16S,17R)-11-ethyl-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.15,8.01,10.02,8.013,17]nonadecane-4,7,16-triol

(1R,2R,4S,5S,7R,8R,9R,10R,13R,16S,17R)-11-ethyl-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.15,8.01,10.02,8.013,17]nonadecane-4,7,16-triol

C22H33NO3 (359.2460308000001)


   

(1R,2S,4S,5S,7R,8R,9R,10R,13R,16S,17S)-11-ethyl-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.15,8.01,10.02,8.013,17]nonadecane-4,7,16-triol

(1R,2S,4S,5S,7R,8R,9R,10R,13R,16S,17S)-11-ethyl-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.15,8.01,10.02,8.013,17]nonadecane-4,7,16-triol

C22H33NO3 (359.2460308000001)


   

2-(3-Hydroxybutoxy)-N-(2-diethylaminoethyl)-4-quinolinecarboxamide

2-(3-Hydroxybutoxy)-N-(2-diethylaminoethyl)-4-quinolinecarboxamide

C20H29N3O3 (359.22088040000006)


   

2-Trimethylsilyloxy-N-(2-(diethylamino)ethyl)-4-quinolinecarboxamide

2-Trimethylsilyloxy-N-(2-(diethylamino)ethyl)-4-quinolinecarboxamide

C19H29N3O2Si (359.2028934)


   

(1R,4S,5S,7R,8R,9R,10R,13R,16S,17S)-11-ethyl-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.15,8.01,10.02,8.013,17]nonadecane-4,7,16-triol

(1R,4S,5S,7R,8R,9R,10R,13R,16S,17S)-11-ethyl-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.15,8.01,10.02,8.013,17]nonadecane-4,7,16-triol

C22H33NO3 (359.2460308000001)


   

gepirone

gepirone

C19H29N5O2 (359.2321134)


D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist N - Nervous system > N06 - Psychoanaleptics > N06A - Antidepressants Gepirone is a selective and affinitive 5-HT1A agonist. Gepirone binds selectively to 5-HT1A receptor binding site. Gepirone acts as an antidepressant agent can be used for anxiety and major depressive disorder research[1].

   

loxtidine

LAVOLTIDINE

C19H29N5O2 (359.2321134)


C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent > C29702 - Histamine-2 Receptor Antagonist D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists

   

(4Z,7Z,10Z,13Z,15E,17S,19Z)-17-hydroperoxydocosahexaenoate

(4Z,7Z,10Z,13Z,15E,17S,19Z)-17-hydroperoxydocosahexaenoate

C22H31O4 (359.2222226)


A hydroperoxydocosahexaenoate that is the conjugate base of (17S)-HPDoHE, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   
   
   

3-hydroxydodecanoylcarnitine

3-hydroxydodecanoylcarnitine

C19H37NO5 (359.26715920000004)


An O-acylcarnitine having 3-hydroxydodecanoyl as the acyl substituent.

   

(4Z,7Z,10Z,12E,14R,16Z,19Z)-14,22-dihydroxydocosahexaenoate

(4Z,7Z,10Z,12E,14R,16Z,19Z)-14,22-dihydroxydocosahexaenoate

C22H31O4 (359.2222226)


A dihydroxydocosahexaenoate that is the conjugate base of (4Z,7Z,10Z,12E,14R,16Z,19Z)-14,22-dihydroxydocosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(7S,14S)-dihydroxy-(4Z,8E,10E,12Z,16Z,19Z)-docosahexaenoate

(7S,14S)-dihydroxy-(4Z,8E,10E,12Z,16Z,19Z)-docosahexaenoate

C22H31O4 (359.2222226)


A dihydroxydocosahexaenoate that is the conjugate base of (7S,14S)-dihydroxy-(4Z,8E,10E,12Z,16Z,19Z)-docosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

oscr#22(1-)

oscr#22(1-)

C19H35O6 (359.243351)


A hydroxy fatty acid ascaroside anion that is the conjugate base of oscr#22, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

resolvin D5(1-)

resolvin D5(1-)

C22H31O4 (359.2222226)


A dihydroxydocosahexaenoate that is the conjugate base of resolvin D5, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(4Z,8E,10Z,12E,14S,16Z,19Z)-14-hydroperoxydocosahexaenoate

(4Z,8E,10Z,12E,14S,16Z,19Z)-14-hydroperoxydocosahexaenoate

C22H31O4 (359.2222226)


A docosanoid anion that is the conjugate base of (4Z,8E,10Z,12E,14S,16Z,19Z)-14-hydroperoxydocosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(4Z,7Z,10Z,12E,14S,16Z,19Z,21R)-dihydroxydocosahexaenoate

(4Z,7Z,10Z,12E,14S,16Z,19Z,21R)-dihydroxydocosahexaenoate

C22H31O4 (359.2222226)


A dihydroxydocosahexaenoate that is the conjugate base of (4Z,7Z,10Z,12E,14S,16Z,19Z,21R)-dihydroxydocosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

7,8-epoxy,17-hydroxy-(9E,11E,13Z,15E,19Z)-docosapentaenoate

7,8-epoxy,17-hydroxy-(9E,11E,13Z,15E,19Z)-docosapentaenoate

C22H31O4 (359.2222226)


A docosanoid anion that is the conjugate base of 7,8-epoxy,17-hydroxy-(9E,11E,13Z,15E,19Z)-docosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

ascr#22(1-)

ascr#22(1-)

C19H35O6 (359.243351)


Conjugate base of ascr#22

   

aspirin-triggered protectin D1(1-)

aspirin-triggered protectin D1(1-)

C22H31O4 (359.2222226)


A dihydroxydocosahexaenoate that is the conjugate base of aspirin-triggered protectin D1, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(4Z,7Z,10Z,12E,14S,16Z,19Z)-14,22-dihydroxydocosahexaenoate

(4Z,7Z,10Z,12E,14S,16Z,19Z)-14,22-dihydroxydocosahexaenoate

C22H31O4 (359.2222226)


A dihydroxydocosahexaenoate that is the conjugate base of (4Z,7Z,10Z,12E,14S,16Z,19Z)-14,22-dihydroxydocosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(4Z,7Z,10Z,12E,14S,16Z,19Z,21S)-dihydroxydocosahexaenoate

(4Z,7Z,10Z,12E,14S,16Z,19Z,21S)-dihydroxydocosahexaenoate

C22H31O4 (359.2222226)


A dihydroxydocosahexaenoate that is the conjugate base of (4Z,7Z,10Z,12E,14S,16Z,19Z,21S)-dihydroxydocosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(4Z,7Z,10Z,12E,14R,16Z,19Z,21R)-dihydroxydocosahexaenoate

(4Z,7Z,10Z,12E,14R,16Z,19Z,21R)-dihydroxydocosahexaenoate

C22H31O4 (359.2222226)


A dihydroxydocosahexaenoate that is the conjugate base of (4Z,7Z,10Z,12E,14R,16Z,19Z,21R)-dihydroxydocosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

asperparaline A

asperparaline A

C20H29N3O3 (359.22088040000006)


An alkaloid isolated from Aspergillus aculeatus.

   

protectin D1(1-)

protectin D1(1-)

C22H31O4 (359.2222226)


A dihydroxydocosahexaenoate that is the conjugate base of protectin D1, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(4Z,7Z,10Z,12E,14R,16Z,19Z,21S)-dihydroxydocosahexaenoate

(4Z,7Z,10Z,12E,14R,16Z,19Z,21S)-dihydroxydocosahexaenoate

C22H31O4 (359.2222226)


A dihydroxydocosahexaenoate that is the conjugate base of (4Z,7Z,10Z,12E,14R,16Z,19Z,21S)-dihydroxydocosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

CarE(12:0)

CarE(12:0(1+O))

C19H37NO5 (359.26715920000004)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   
   
   
   
   

11-ethyl-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecane-4,7,16-triol

11-ethyl-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecane-4,7,16-triol

C22H33NO3 (359.2460308000001)


   

1,4',4',12',14'-pentamethyl-9',14'-diazaspiro[pyrrolidine-3,5'-tetracyclo[5.5.2.0¹,⁹.0³,⁷]tetradecane]-2,5,13'-trione

1,4',4',12',14'-pentamethyl-9',14'-diazaspiro[pyrrolidine-3,5'-tetracyclo[5.5.2.0¹,⁹.0³,⁷]tetradecane]-2,5,13'-trione

C20H29N3O3 (359.22088040000006)


   

(1r,2s,5r,8r,9r,10s,11r,13r,14s,15r,16r)-7-ethyl-5-methyl-12-methylidene-7-azahexacyclo[7.6.2.2¹⁰,¹³.0¹,⁸.0⁵,¹⁶.0¹⁰,¹⁵]nonadecane-2,11,14-triol

(1r,2s,5r,8r,9r,10s,11r,13r,14s,15r,16r)-7-ethyl-5-methyl-12-methylidene-7-azahexacyclo[7.6.2.2¹⁰,¹³.0¹,⁸.0⁵,¹⁶.0¹⁰,¹⁵]nonadecane-2,11,14-triol

C22H33NO3 (359.2460308000001)


   

(1's,3s,3's,7'r,12's)-1,4',4',12',14'-pentamethyl-9',14'-diazaspiro[pyrrolidine-3,5'-tetracyclo[5.5.2.0¹,⁹.0³,⁷]tetradecane]-2,5,13'-trione

(1's,3s,3's,7'r,12's)-1,4',4',12',14'-pentamethyl-9',14'-diazaspiro[pyrrolidine-3,5'-tetracyclo[5.5.2.0¹,⁹.0³,⁷]tetradecane]-2,5,13'-trione

C20H29N3O3 (359.22088040000006)


   

(3r,5s)-3-[(1r,2r,4as,8as)-2,3,6-trimethyl-1,2,4a,5,8,8a-hexahydronaphthalene-1-carbonyl]-5-(2-methylpropyl)-4,5-dihydropyrrole-2,3-diol

(3r,5s)-3-[(1r,2r,4as,8as)-2,3,6-trimethyl-1,2,4a,5,8,8a-hexahydronaphthalene-1-carbonyl]-5-(2-methylpropyl)-4,5-dihydropyrrole-2,3-diol

C22H33NO3 (359.2460308000001)


   

(4s)-4-amino-4-{[(1s,2s)-1-{[(1s)-1-carboxy-2-methylpropyl]-c-hydroxycarbonimidoyl}-2-methylbutyl]-c-hydroxycarbonimidoyl}butanoic acid

(4s)-4-amino-4-{[(1s,2s)-1-{[(1s)-1-carboxy-2-methylpropyl]-c-hydroxycarbonimidoyl}-2-methylbutyl]-c-hydroxycarbonimidoyl}butanoic acid

C16H29N3O6 (359.20562540000003)


   

(1r,7r,10r,18s,22r,23s)-15-hydroxy-11-methyl-5-oxa-13-azahexacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁸,²²]tricosan-4-one

(1r,7r,10r,18s,22r,23s)-15-hydroxy-11-methyl-5-oxa-13-azahexacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁸,²²]tricosan-4-one

C22H33NO3 (359.2460308000001)


   

7-ethenyl-1,1,4a,7-tetramethyl-3,4,6,8,8a,9,10,10a-octahydro-2h-phenanthren-2-yl carbamoylformate

7-ethenyl-1,1,4a,7-tetramethyl-3,4,6,8,8a,9,10,10a-octahydro-2h-phenanthren-2-yl carbamoylformate

C22H33NO3 (359.2460308000001)


   

4-[(1s,2r,4as,6r,8ar)-1,3,6-trimethyl-2-propyl-4a,5,6,7,8,8a-hexahydro-2h-naphthalene-1-carbonyl]-3,5-dihydroxypyrrol-2-one

4-[(1s,2r,4as,6r,8ar)-1,3,6-trimethyl-2-propyl-4a,5,6,7,8,8a-hexahydro-2h-naphthalene-1-carbonyl]-3,5-dihydroxypyrrol-2-one

C21H29NO4 (359.20964740000005)


   

4-hydroxy-6-methoxy-3-methyl-2-(8-methyldeca-2,4,6-trien-2-yl)-2h,3h,4h-pyrano[3,2-c]pyridin-5-one

4-hydroxy-6-methoxy-3-methyl-2-(8-methyldeca-2,4,6-trien-2-yl)-2h,3h,4h-pyrano[3,2-c]pyridin-5-one

C21H29NO4 (359.20964740000005)


   

(1r,5r,6r,7r,8s,9r,13r,16s,17s)-11-ethyl-7,16-dihydroxy-6,13-dimethyl-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecan-4-one

(1r,5r,6r,7r,8s,9r,13r,16s,17s)-11-ethyl-7,16-dihydroxy-6,13-dimethyl-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecan-4-one

C22H33NO3 (359.2460308000001)


   

4-[(1r,2r,4ar,6r,8ar)-1,3,6-trimethyl-2-propyl-4a,5,6,7,8,8a-hexahydro-2h-naphthalene-1-carbonyl]-3,5-dihydroxypyrrol-2-one

4-[(1r,2r,4ar,6r,8ar)-1,3,6-trimethyl-2-propyl-4a,5,6,7,8,8a-hexahydro-2h-naphthalene-1-carbonyl]-3,5-dihydroxypyrrol-2-one

C21H29NO4 (359.20964740000005)


   

(2s,4e)-4-{[(1s,2r,4as,6r,8ar)-1,6-dimethyl-2-[(1e)-prop-1-en-1-yl]-4a,5,6,7,8,8a-hexahydro-2h-naphthalen-1-yl](hydroxy)methylidene}-5-hydroxy-2-(hydroxymethyl)-2h-pyrrol-3-one

(2s,4e)-4-{[(1s,2r,4as,6r,8ar)-1,6-dimethyl-2-[(1e)-prop-1-en-1-yl]-4a,5,6,7,8,8a-hexahydro-2h-naphthalen-1-yl](hydroxy)methylidene}-5-hydroxy-2-(hydroxymethyl)-2h-pyrrol-3-one

C21H29NO4 (359.20964740000005)


   

4,5,6,17-tetramethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,14-tetraene

4,5,6,17-tetramethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,14-tetraene

C21H29NO4 (359.20964740000005)


   

(1s,5r,8r,10r,11s,14s,16r,17r)-7-(2-hydroxyethyl)-5-methyl-13-methylidene-9-oxa-7-azahexacyclo[8.6.2.2¹¹,¹⁴.0¹,⁸.0⁵,¹⁷.0¹¹,¹⁶]icosan-12-ol

(1s,5r,8r,10r,11s,14s,16r,17r)-7-(2-hydroxyethyl)-5-methyl-13-methylidene-9-oxa-7-azahexacyclo[8.6.2.2¹¹,¹⁴.0¹,⁸.0⁵,¹⁷.0¹¹,¹⁶]icosan-12-ol

C22H33NO3 (359.2460308000001)


   

(1s,2s,4s,5r,7r,8r,9s,10s,13s,16r,17s)-11-ethyl-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecane-4,7,16-triol

(1s,2s,4s,5r,7r,8r,9s,10s,13s,16r,17s)-11-ethyl-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecane-4,7,16-triol

C22H33NO3 (359.2460308000001)


   

(2s,4z)-4-{[(1s,4as,6r,8ar)-1,6-dimethyl-2-[(1e)-prop-1-en-1-yl]-4a,5,6,7,8,8a-hexahydro-2h-naphthalen-1-yl](hydroxy)methylidene}-5-hydroxy-2-(hydroxymethyl)-2h-pyrrol-3-one

(2s,4z)-4-{[(1s,4as,6r,8ar)-1,6-dimethyl-2-[(1e)-prop-1-en-1-yl]-4a,5,6,7,8,8a-hexahydro-2h-naphthalen-1-yl](hydroxy)methylidene}-5-hydroxy-2-(hydroxymethyl)-2h-pyrrol-3-one

C21H29NO4 (359.20964740000005)


   

(4s,4ar,6s,7r,7as)-2,4,7-trimethyl-octahydrocyclopenta[c]pyridin-6-yl (2e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate

(4s,4ar,6s,7r,7as)-2,4,7-trimethyl-octahydrocyclopenta[c]pyridin-6-yl (2e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate

C21H29NO4 (359.20964740000005)


   

(1s,2s,4s,6r,7s,10r,11r)-6-hydroxy-13-(2-hydroxyethyl)-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadecan-8-one

(1s,2s,4s,6r,7s,10r,11r)-6-hydroxy-13-(2-hydroxyethyl)-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadecan-8-one

C22H33NO3 (359.2460308000001)


   

2-{6,8-dihydroxy-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadecan-13-yl}acetaldehyde

2-{6,8-dihydroxy-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadecan-13-yl}acetaldehyde

C22H33NO3 (359.2460308000001)


   

(1r,5r,8r,10s,11r,14s,16r,17r,18s)-7-(2-hydroxyethyl)-5-methyl-13-methylidene-9-oxa-7-azahexacyclo[8.6.2.2¹¹,¹⁴.0¹,⁸.0⁵,¹⁷.0¹¹,¹⁶]icosan-18-ol

(1r,5r,8r,10s,11r,14s,16r,17r,18s)-7-(2-hydroxyethyl)-5-methyl-13-methylidene-9-oxa-7-azahexacyclo[8.6.2.2¹¹,¹⁴.0¹,⁸.0⁵,¹⁷.0¹¹,¹⁶]icosan-18-ol

C22H33NO3 (359.2460308000001)


   

11-ethyl-4,16-dihydroxy-6,13-dimethyl-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecan-7-one

11-ethyl-4,16-dihydroxy-6,13-dimethyl-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecan-7-one

C22H33NO3 (359.2460308000001)


   

(1s,2s,4r,7s,8r,10r,11r)-8-hydroxy-13-(2-hydroxyethyl)-11-methyl-19-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadecan-6-one

(1s,2s,4r,7s,8r,10r,11r)-8-hydroxy-13-(2-hydroxyethyl)-11-methyl-19-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadecan-6-one

C22H33NO3 (359.2460308000001)